.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Teva
Boehringer Ingelheim
Harvard Business School
McKesson
Cantor Fitzgerald
UBS
US Department of Justice
Citi

Generated: November 24, 2017

DrugPatentWatch Database Preview

TARO Company Profile

« Back to Dashboard

What is the competitive landscape for TARO, and when can generic versions of TARO drugs launch?

TARO has two hundred and five approved drugs.

There are ten US patents protecting TARO drugs. There are three tentative approvals on TARO drugs.

There are sixty-two patent family members on TARO drugs in seventeen countries and sixty-nine supplementary protection certificates in eleven countries.

Summary for TARO

International Patents:62
US Patents:10
Tradenames:105
Ingredients:89
NDAs:205
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro
RANITIDINE HYDROCHLORIDE
ranitidine hydrochloride
SYRUP;ORAL077476-001Jun 13, 2011AARXNoNo► Subscribe► Subscribe► Subscribe
Taro
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
OINTMENT, AUGMENTED;TOPICAL076753-001Oct 12, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
HYDROCORTISONE
hydrocortisone
CREAM;TOPICAL088799-001Nov 9, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe
Taro
U-CORT
hydrocortisone acetate; urea
CREAM;TOPICAL089472-001Jun 13, 1988RXNoNo► Subscribe► Subscribe► Subscribe
Taro
NYSTATIN
nystatin
CREAM;TOPICAL064022-001Jan 29, 1993ATRXNoYes► Subscribe► Subscribe► Subscribe
Taro
CARBAMAZEPINE
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL201106-002Jun 21, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
TOPICORT
desoximetasone
SPRAY;TOPICAL204141-001Apr 11, 2013ATRXYesYes► Subscribe► SubscribeY ► Subscribe
Taro
CLOTRIMAZOLE
clotrimazole
CREAM;TOPICAL072640-001Aug 31, 1993ABRXNoYes► Subscribe► Subscribe► Subscribe
Taro Pharms North
INFANTS' FEVERALL
acetaminophen
SUPPOSITORY;RECTAL018337-004Aug 26, 1992OTCYesNo► Subscribe► Subscribe► Subscribe
Taro
FLUCONAZOLE
fluconazole
TABLET;ORAL076507-001Jul 29, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
Taro Pharms
PLIAGLIS
lidocaine; tetracaine
CREAM;TOPICAL021717-001Jun 29, 2006► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TARO drugs

Drugname Dosage Strength Tradename Submissiondate
desoximetasone
Topical Spray0.25%
TOPICORT
12/18/2013
malathion
Topical Lotion0.5%
OVIDE
3/16/2011

Premature patent expirations for TARO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Taro

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,038 Composition and method for treatment of psoriasis► Subscribe
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
8,206,727Oral suspension of prednisolone acetate► Subscribe
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
8,461,139Oral suspension of prednisolone acetate► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
6,355,258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taro Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006130510► Subscribe
Japan2009079053► Subscribe
European Patent Office1898707► Subscribe
World Intellectual Property Organization (WIPO)2007019184► Subscribe
World Intellectual Property Organization (WIPO)0122907► Subscribe
Canada2333405► Subscribe
Germany69939792► Subscribe
South Korea20080044245► Subscribe
Australia2003271358► Subscribe
Spain2276697► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taro Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
01C/013Belgium► SubscribePRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
80024Netherlands► SubscribePRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
C0024France► SubscribePRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
C/GB99/003United Kingdom► SubscribePRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
00C/032Belgium► SubscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Dow
Chubb
Chinese Patent Office
Mallinckrodt
US Department of Justice
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot